Francisco Lozano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7716818/publications.pdf

Version: 2024-02-01

122 3,906 33 57
papers citations h-index g-index

125 125 125 125 4634

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma. Cancer Immunology, Immunotherapy, 2022, 71, 1837-1849.	4.2	2
2	Gene Variation at Immunomodulatory and Cell Adhesion Molecules Loci Impacts Primary Sjögren's Syndrome. Frontiers in Medicine, 2022, 9, 822290.	2.6	0
3	Innate immune response to peritoneal bacterial infection. International Review of Cell and Molecular Biology, 2022, , .	3.2	1
4	Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution. Prostate, 2022, 82, 1331-1337.	2.3	2
5	The lymphocyte scavenger receptor CD5 plays a nonredundant role in fungal infection. Cellular and Molecular Immunology, 2021, 18, 498-500.	10.5	4
6	Contribution of Evolutionary Selected Immune Gene Polymorphism to Immune-Related Disorders: The Case of Lymphocyte Scavenger Receptors CD5 and CD6. International Journal of Molecular Sciences, 2021, 22, 5315.	4.1	6
7	Study of Biocompatibility of Membranes in Online Hemodiafiltration. Blood Purification, 2020, 49, 400-408.	1.8	6
8	The Lymphocytic Scavenger Receptor CD5 Shows Therapeutic Potential in Mouse Models of Fungal Infection. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	1
9	Interactome analysis of CD5 and CD6 ectodomains with tegumental antigens from the helminth parasite Echinococcus granulosus sensu lato. International Journal of Biological Macromolecules, 2020, 164, 3718-3728.	7.5	3
10	Mammalian lipid droplets are innate immune hubs integrating cell metabolism and host defense. Science, 2020, 370, .	12.6	245
11	CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 1074-1083.	2.8	14
12	Soluble CD5 and CD6: Lymphocytic Class I Scavenger Receptors as Immunotherapeutic Agents. Cells, 2020, 9, 2589.	4.1	12
13	Multifaceted effects of soluble human CD6 in experimental cancer models. , 2020, 8, e000172.		7
14	Treatment of Experimental Autoimmune Encephalomyelitis by Sustained Delivery of Low-Dose IFN-α. Journal of Immunology, 2019, 203, 696-704.	0.8	6
15	Discordant susceptibility of inbred C57BL/6 versus outbred CD1 mice to experimental fungal sepsis. Cellular Microbiology, 2019, 21, e12995.	2.1	12
16	Clinical and experimental evidence for targeting CD6 in immune-based disorders. Autoimmunity Reviews, 2018, 17, 493-503.	5.8	28
17	Gut microbiota metabolites for sweetening type I diabetes. Cellular and Molecular Immunology, 2018, 15, 92-95.	10.5	9
18	Cytokines as therapeutic targets in primary Sjögren syndrome. , 2018, 184, 81-97.		23

#	Article	IF	CITATIONS
19	Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis. Cellular and Molecular Immunology, 2018, 15, 898-906.	10.5	17
20	Mannose Binding Lectin (mbl2) Genotype Frequencies in Solid Organ Transplant Patients. Transplantation, 2018, 102, S688.	1.0	0
21	The ectodomains of the lymphocyte scavenger receptors CD5 and CD6 interact with tegumental antigens from Echinococcus granulosus sensu lato and protect mice against secondary cystic echinococcosis. PLoS Neglected Tropical Diseases, 2018, 12, e0006891.	3.0	9
22	Conserved Bacterial-Binding Peptides of the Scavenger-Like Human Lymphocyte Receptor CD6 Protect From Mouse Experimental Sepsis. Frontiers in Immunology, 2018, 9, 627.	4.8	6
23	Exploiting scavenger receptors in cancer immunotherapy: Lessons from CD5 and SRâ€B1. European Journal of Immunology, 2017, 47, 1108-1118.	2.9	23
24	Protective Effects of Human and Mouse Soluble Scavenger-Like CD6 Lymphocyte Receptor in a Lethal Model of Polymicrobial Sepsis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	10
25	Oral Administration of Pentoxifylline Reduces Endometriosis-Like Lesions in a Nude Mouse Model. Reproductive Sciences, 2017, 24, 911-918.	2.5	8
26	Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens. British Journal of Haematology, 2017, 177, 147-150.	2.5	8
27	Commentary: The Scavenger Receptor SSc5D Physically Interacts with Bacteria through the SRCR-Containing N-Terminal Domain. Frontiers in Immunology, 2017, 8, 366.	4.8	2
28	Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance. Frontiers in Immunology, 2017, 8, 594.	4.8	12
29	Human CD6 Down-Modulation following T-Cell Activation Compromises Lymphocyte Survival and Proliferative Responses. Frontiers in Immunology, 2017, 8, 769.	4.8	17
30	Commentary: CD6 As a Potential Target for Treating Multiple Sclerosis. Frontiers in Immunology, 2017, 8, 1217.	4.8	3
31	Mannose-binding lectin-deficient genotypes as a risk factor of pneumococcal meningitis in infants. PLoS ONE, 2017, 12, e0178377.	2.5	8
32	Immunomodulatory effects of soluble CD5 on experimental tumor models. Oncotarget, 2017, 8, 108156-108169.	1.8	8
33	Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival. International Journal of Cancer, 2016, 139, 1297-1302.	5.1	14
34	CD6 modulates thymocyte selection and peripheral T cell homeostasis. Journal of Experimental Medicine, 2016, 213, 1387-1397.	8.5	68
35	Natural Killer Cells Transfer Antimicrobial and Antitumoral Histone H2AZ to Kill Multiple Myeloma Cells Contributing to Transmissible Cytotoxicity. Blood, 2016, 128, 2115-2115.	1.4	1
36	Pattern Recognition by CD6: A Scavenger-Like Lymphocyte Receptor. Current Drug Targets, 2016, 17, 640-650.	2.1	14

#	Article	IF	CITATIONS
37	Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1–Infected Patients Starting Efavirenz, Lopinavir–Ritonavir, or Atazanavir–Ritonavir Plus Tenofovir/Emtricitabine. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 206-215.	2.1	14
38	CD5 as a Target for Immune-Based Therapies. Critical Reviews in Immunology, 2015, 35, 85-115.	0.5	20
39	Pattern of soluble CD5 and CD6 lymphocyte receptors in critically ill patients with septic syndromes. Journal of Critical Care, 2015, 30, 914-919.	2.2	13
40	Etiopathogenic Role of Surfactant Protein D in the Clinical and Immunological Expression of Primary Sjögren Syndrome. Journal of Rheumatology, 2015, 42, 111-118.	2.0	12
41	Tollâ€like receptor 9 promoter polymorphism as a predictive factor of narrowâ€band <scp>UVB</scp> phototherapy response in patients with psoriasis. Photodermatology Photoimmunology and Photomedicine, 2015, 31, 98-103.	1.5	9
42	Functional requirement of tyrosine residue 429 within CD5 cytoplasmic domain for regulation of T cell activation and survival. Biochemical and Biophysical Research Communications, 2015, 466, 381-387.	2.1	9
43	Transgenic Expression of Soluble Human CD5 Enhances Experimentally-Induced Autoimmune and Anti-Tumoral Immune Responses. PLoS ONE, 2014, 9, e84895.	2.5	16
44	The macrophage soluble receptor AIM/Api6/CD5L displays a broad pathogen recognition spectrum and is involved in early response to microbial aggression. Cellular and Molecular Immunology, 2014, 11, 343-354.	10.5	39
45	Targeting of Key Pathogenic Factors From Gram-Positive Bacteria by the Soluble Ectodomain of the Scavenger-Like Lymphocyte Receptor CD6. Journal of Infectious Diseases, 2014, 209, 1077-1086.	4.0	16
46	Expression of the innate defense receptor <scp>S5Dâ€SRCRB</scp> in the urogenital tract. Tissue Antigens, 2014, 83, 273-285.	1.0	5
47	A Role for Scavenger-like Lymphocyte Receptor CD6 in HIV-1 Viral Infection. AIDS Research and Human Retroviruses, 2014, 30, A49-A50.	1.1	8
48	Modulation of CD6 function through interaction with Galectinâ€1 and â€3. FEBS Letters, 2014, 588, 2805-2813.	2.8	22
49	Immune and Stress Mediators in Response to Bilateral Adnexectomy: Comparison of Single-Port Access and Conventional Laparoscopy in a Porcine Model. Journal of Minimally Invasive Gynecology, 2014, 21, 837-843.	0.6	3
50	Analysis of Ancestral and Functionally Relevant CD5 Variants in Systemic Lupus Erythematosus Patients. PLoS ONE, 2014, 9, e113090.	2.5	15
51	Genetic variants of innate immune receptors and infections after liver transplantation. World Journal of Gastroenterology, 2014, 20, 11116.	3.3	9
52	The carboxy-terminal region of CD5 is required for c-CBL mediated TCR signaling downmodulation in thymocytes. Biochemical and Biophysical Research Communications, 2013, 432, 52-59.	2.1	10
53	Identification of functionally relevant phoshorylatable serine clusters in the cytoplasmic region of the human CD6 lymphocyte surface receptor. FEBS Letters, 2013, 587, 2205-2213.	2.8	14
54	The Role of Fcî³ Receptor Polymorphisms in the Response to Anti–Tumor Necrosis Factor Therapy in Psoriasis. JAMA Dermatology, 2013, 149, 1033.	4.1	38

#	Article	IF	CITATIONS
55	Evolutionary and Functional Evidence for Positive Selection at the Human CD5 Immune Receptor Gene. Molecular Biology and Evolution, 2012, 29, 811-823.	8.9	20
56	Association of syntenin-1 with M-RIP polarizes Rac-1 activation during chemotaxis and immune interactions. Journal of Cell Science, 2012, 125, 1235-1246.	2.0	33
57	FCGR2A/CD32AandFCGR3A/CD16AVariants and EULAR Response to Tumor Necrosis Factor-α Blockers in Psoriatic Arthritis: A Longitudinal Study with 6 Months of Followup. Journal of Rheumatology, 2012, 39, 1035-1041.	2.0	29
58	Ovarian endometrioma but not deep infiltrating endometriosis is associated with increased serum levels of interleukin-8 and interleukin-6. Journal of Reproductive Immunology, 2012, 95, 80-86.	1.9	38
59	A case of aggressive bullous pemphigoid associated with the defective functional variant of Fc gamma receptor IIb: Implications for pathogenesis?. Journal of the American Academy of Dermatology, 2011, 65, 1062-1063.	1.2	3
60	The Conserved Scavenger Receptor Cysteine-Rich Superfamily in Therapy and Diagnosis. Pharmacological Reviews, 2011, 63, 967-1000.	16.0	157
61	The immunomodulatory properties of the CD5 lymphocyte receptor in health and disease. Current Opinion in Immunology, 2011, 23, 310-318.	5.5	66
62	Role of CD5/CD5L interactions in the homeostasis of regulatory lymphocyte subpopulations and the control of autoimmune disorders. Journal of Translational Medicine, 2011, 9, O6.	4.4	2
63	Liver X Receptors Inhibit Macrophage Proliferation through Downregulation of Cyclins D1 and B1 and Cyclin-Dependent Kinases 2 and 4. Journal of Immunology, 2011, 186, 4656-4667.	0.8	25
64	Basophils, IgE, and Autoantibody-Mediated Kidney Disease. Journal of Immunology, 2011, 186, 6083-6090.	0.8	19
65	Molecular and Functional Characterization of Mouse S5D-SRCRB: A New Group B Member of the Scavenger Receptor Cysteine-Rich Superfamily. Journal of Immunology, 2011, 186, 2344-2354.	0.8	19
66	Therapeutic Targeting of B Cells for Rheumatic Autoimmune Diseases. Pharmacological Reviews, 2011, 63, 127-156.	16.0	95
67	Genotypes Coding for Low Serum Levels of Mannose-Binding Lectin Are Underrepresented among Individuals Suffering from Noninfectious Systemic Inflammatory Response Syndrome. Vaccine Journal, 2010, 17, 447-453.	3.1	8
68	Elevated numbers of SCART1+ $\hat{I}^3\hat{I}$ T cells in skin inflammation and inflammatory bowel disease. Molecular lmmunology, 2010, 47, 1710-1718.	2.2	12
69	The role of Fc gamma receptors polymorphisms in bullous pemphigoid. Journal of the American Academy of Dermatology, 2010, 63, 161-163.	1.2	4
70	Genetically-Defined Deficiency of Mannose-Binding Lectin Is Associated with Protection after Experimental Stroke in Mice and Outcome in Human Stroke. PLoS ONE, 2010, 5, e8433.	2.5	128
71	The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1506-1511.	7.1	117
72	Increased numbers of thymic and peripheral CD4 ⁺ CD25 ⁺ Foxp3 ⁺ cells in the absence of CD5 signaling. European Journal of Immunology, 2009, 39, 2233-2247.	2.9	43

#	Article	IF	CITATIONS
73	Donor mannose-binding lectin gene polymorphisms influence the outcome of liver transplantation. Liver Transplantation, 2009, 15, 1217-1224.	2.4	47
74	Genetic and structural analysis of <i>MBL2</i> and <i>MASP2</i> polymorphisms in southâ€eastern African children. Tissue Antigens, 2009, 74, 298-307.	1.0	16
75	The human CD6 gene is transcriptionally regulated by RUNX and Ets transcription factors in T cells. Molecular Immunology, 2009, 46, 2226-2235.	2.2	19
76	Polymorphic Receptors of the Innate Immune System (MBL/MASP-2 and TLR2/4) and Susceptibility to Pneumococcal Bacteremia in HIV-Infected Patients: A Case-Control Study. Current HIV Research, 2009, 7, 218-223.	0.5	14
77	Is Mannoseâ€Binding Lectin Deficiency Associated with Infection due to Gramâ€Positive Bacteria?. Clinical Infectious Diseases, 2008, 47, 1492-1493.	5.8	7
78	CD6 binds to pathogen-associated molecular patterns and protects from LPS-induced septic shock. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 11724-11729.	7.1	100
79	Association between Mannose-Binding Lectin Deficiency and Septic Shock following Acute Pyelonephritis Due to Escherichia coli. Vaccine Journal, 2007, 14, 256-261.	3.1	23
80	Crystal Structure of the Third Extracellular Domain of CD5 Reveals the Fold of a Group B Scavenger Cysteine-rich Receptor Domain. Journal of Biological Chemistry, 2007, 282, 12669-12677.	3.4	40
81	The Influence of Innate Immunity Gene Receptors Polymorphisms in Renal Transplant Infections. Transplantation, 2007, 83, 1493-1500.	1.0	77
82	Expression, purification and crystallization of human CD5 domain III, a nano-scale crystallization example. Journal of Structural Biology, 2007, 159, 144-148.	2.8	3
83	Identification and Functional Characterization of the Hepatic Stellate Cell CD38 Cell Surface Molecule. American Journal of Pathology, 2007, 170, 176-187.	3.8	44
84	Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Experimental Hematology, 2006, 34, 1435-1441.	0.4	89
85	Mitogen-Activated Protein Kinase Pathway Activation by the CD6 Lymphocyte Surface Receptor. Journal of Immunology, 2006, 177, 1152-1159.	0.8	45
86	Polymorphisms in the interleukin-4 receptor $\hat{l}\pm$ chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. Immunogenetics, 2005, 57, 644-654.	2.4	25
87	A Role for Human SPÎ \pm as a Pattern Recognition Receptor. Journal of Biological Chemistry, 2005, 280, 35391-35398.	3.4	97
88	The Lymphocyte Receptor CD6 Interacts with Syntenin-1, a Scaffolding Protein Containing PDZ Domains. Journal of Immunology, 2005, 175, 1406-1414.	0.8	57
89	Expression of Interleukin-8 Receptors (CXCR1 and CXCR2) in Premenopausal Women with Recurrent Urinary Tract Infections. Vaccine Journal, 2005, 12, 1358-1363.	3.1	40
90	Transcriptional Regulation of Human CD5: Important Role of Ets Transcription Factors in CD5 Expression in T Cells. Journal of Immunology, 2004, 172, 7519-7529.	0.8	22

#	Article	IF	Citations
91	Relevance of CD6-Mediated Interactions in T Cell Activation and Proliferation. Journal of Immunology, 2004, 173, 2262-2270.	0.8	130
92	Donor's Mannan-Binding Lectin (MBL) Gene Polymorphism Is Associated with Invasive Fungal Infection Following Allogeneic Stem Cell Transplantation Blood, 2004, 104, 2220-2220.	1.4	2
93	The Scavenger Receptor Cysteine-Rich (SRCR) Domain: An Ancient and Highly Conserved Protein Module of the Innate Immune System. Critical Reviews in Immunology, 2004, 24, 1-38.	0.5	226
94	The Accessory Molecules CD5 and CD6 Associate on the Membrane of Lymphoid T Cells. Journal of Biological Chemistry, 2003, 278, 8564-8571.	3.4	65
95	A Novel Serine-rich Motif in the Intercellular Adhesion Molecule 3 Is Critical for Its Ezrin/Radixin/Moesin-directed Subcellular Targeting. Journal of Biological Chemistry, 2002, 277, 10400-10409.	3.4	64
96	Cloning of S4D-SRCRB, a new soluble member of the group B scavenger receptor cysteine-rich family (SRCR-SF) mapping to human Chromosome 7q11.23. Immunogenetics, 2002, 54, 621-634.	2.4	13
97	Residues Y429 and Y463 of the human CD5 are targeted by protein tyrosine kinases. European Journal of Immunology, 2001, 31, 1191-1198.	2.9	22
98	Role of Two Conserved Cytoplasmic Threonine Residues (T410 and T412) in CD5 Signaling. Journal of Immunology, 2001, 166, 396-402.	0.8	14
99	Genomic organization of the human CD5 gene. Immunogenetics, 2000, 51, 993-1001.	2.4	40
100	Polarization and interaction of adhesion molecules P-selectin glycoprotein ligand 1 and intercellular adhesion molecule 3 with moesin and ezrin in myeloid cells. Blood, 2000, 95, 2413-2419.	1.4	106
101	CD5 Signal Transduction: Positive or Negative Modulation of Antigen Receptor Signaling. Critical Reviews in Immunology, 2000, 20, 12.	0.5	57
102	Polarization and interaction of adhesion molecules P-selectin glycoprotein ligand 1 and intercellular adhesion molecule 3 with moesin and ezrin in myeloid cells. Blood, 2000, 95, 2413-2419.	1.4	6
103	Interaction of recombinant and natural soluble CD5 forms with an alternative cell surface ligand. European Journal of Immunology, 1999, 29, 2119-2129.	2.9	55
104	CD43 Interacts With Moesin and Ezrin and Regulates Its Redistribution to the Uropods of T Lymphocytes at the Cell-Cell Contacts. Blood, 1998, 91, 4632-4644.	1.4	15
105	Moesin Interacts with the Cytoplasmic Region of Intercellular Adhesion Molecule-3 and Is Redistributed to the Uropod of T Lymphocytes during Cell Polarization. Journal of Cell Biology, 1997, 138, 1409-1423.	5.2	212
106	Conservation of a polymorphic microsatellite at orthologous positions in the human and mouse CD5 gene promoter. Immunogenetics, 1997, 45, 233-234.	2.4	5
107	Conformation of the hypervariable region L3 without the key proline residue. Protein Science, 1996, 5, 167-169.	7.6	20
108	A Reporter Gene to Analyse the Hypermutation of Immunoglobulin Genes. Journal of Molecular Biology, 1995, 249, 555-563.	4.2	13

#	Article	IF	Citations
109	Affinity maturation leads to differential expression of multiple copies of a \hat{l}^{0} light-chain transgene. Nature, 1993, 363, 271-273.	27.8	41
110	Isolation and characterisation of a CDw50 negative Jurkat T-cell line variant (PPL.1). Leukemia Research, 1993, 17, 9-16.	0.8	7
111	Different Mechanisms Regulate the Monoclonal Antibody-Induced Modulation of CD2, CD3, and CD5 in Human Lymphocytes. Cellular Immunology, 1993, 147, 247-255.	3.0	8
112	Effect of protein kinase C activators on the phosphorylation and the surface expression of the CDw50 leukocyte antigen. FEBS Journal, 1992, 203, 321-326.	0.2	14
113	Impaired post-transcriptional expression of interleukin-2 receptor in pokeweed mitogen-activated T cells. European Journal of Immunology, 1992, 22, 897-902.	2.9	10
114	Induction of interleukin 2 (IL2) and interferon- \hat{I}^3 and enhancement of IL2 receptor expression by a CD26 monoclonal antibody. European Journal of Immunology, 1991, 21, 1085-1088.	2.9	29
115	The Protein Kinase C-Independent Human B Cell Proliferation Induced via Surface Immunoglobulins is Unaffected by CD45 Monoclonal Antibodies. Immunobiology, 1991, 182, 152-160.	1.9	0
116	Involvement of the CDw50 molecule in allorecognition. Tissue Antigens, 1990, 36, 203-210.	1.0	31
117	Phosphorylation-mediated changes in the electrophoretic mobility of CD5 molecules. FEBS Journal, 1990, 193, 469-477.	0.2	13
118	Differential effects of anti-CD45 monoclonal antibody on human B cell proliferation: a monoclonal antibody recognizing a neuraminidase-sensitive epitope of the T200 molecule enhances anti-immunoglobulin-induced proliferation. European Journal of Immunology, 1990, 20, 2801-2804.	2.9	19
119	Persistent Low C3 Levels Associated with Meningococcal Meningitis and Membranoproliferative Glomerulonephritis. American Journal of Nephrology, 1990, 10, 426-430.	3.1	9
120	Identification of the amino acid residues defining an intralocus determinant in the $\hat{l}\pm 1$ domain of HLA-A molecules. Immunogenetics, 1989, 30, 50-53.	2.4	27
121	Autoantibodies against nuclear envelope-associated proteins in primary biliary cirrhosis. Hepatology, 1988, 8, 930-938.	7.3	101
122	CD43 monoclonal antibodies recognize the large sialoglycoprotein of human leukocytes. European Journal of Immunology, 1987, 17, 1523-1526.	2.9	68